With the help of the development of information technology (IT), genetic analysis technology has shown its rapid progress. In the past, analyzing human genome required at least 10 years and a 300 billion yen budge. Nowadays its analytical term is about 7 days and a 500,000 yen’s budget. Taking advantage of this technology paved the way for precision medicine. This medical model proposes to analyze cancer cell genetics and tailor products to respective types of cancers.
The main cause of cancer happens when abnormal cell growth invades or spreads through the body. Abnormal cell growth causes the occurrence of abnormal protein which leads to cancer cell growth. If gene mutation of cancer cells, which cause abnormal protein growth, can be identified, the suppression of abnormal protein growth is a real possibility. In other words, medicine effective in suppressing abnormal protein growth could be used to cure cancer. In cancer, depending on the type of treatments, drugs or other substances to target specific molecules are used, which are called ‘molecular targeted drugs.’ Although the progress of precision medicine technology has shown its partial improvement in rare cancer treatments, the number of medical institutions and analytical centers specializing in this area are still limited in Japan.
Nonetheless, regarding the analysis of the abnormal growth of cancer cells, we are promoting partnerships with medical institutions and laboratory centers not only in Japan, but also overseas. We are committed to moving beyond the normal practices of today, and furthering the advancement of the utilization of precision medicine in medical institutions.